Short answer
Inhibrx Biosciences, Inc. (INBX) filed an 8-K current report with the SEC on April 21, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Ozekibart (INBRX-109) clinical updates in late-line colorectal cancer, potentially affecting development outlook.
Inhibrx Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Ozekibart (INBRX-109) clinical updates in late-line colorectal cancer, potentially affecting development outlook
- April 21, 2026 press release contains the substantive clinical data and disclosures
Item 8.01 · Other Events
- Ozekibart plus FOLFIRI produced 20% ORR among 45 evaluable, heavily pretreated CRC patients versus historical 1–6% standard-of-care ORR
- Median PFS 5.5 months, with 42% progression-free at six months and 9 patients remaining on therapy
- 87% disease-control rate and responses across RAS/RAF mutation status support potential activity beyond narrowly defined biomarker groups
- Manageable safety profile, with mostly Grade 1–2 diarrhea, fatigue, and nausea despite liver metastases in 68% of patients
- FDA discussions planned for a first-line CRC registrational trial and potential accelerated pathways; BLA submitted for conventional chondrosarcoma in April 2026
Item EX-99.1 · Exhibit EX-99.1
- Interim CRC data: 20% ORR among 45 evaluable patients versus historical standard-of-care ORR of 1–6%
- Median PFS 5.5 months, with 42% progression-free at six months and nine patients still on therapy
- DCR 87%; nearly half of responses lasted beyond six months, including across RAS/RAF mutation status
- Manageable safety profile, with mostly Grade 1–2 diarrhea, fatigue, and nausea despite 68% liver metastases
- FDA discussions planned for second-line registrational CRC trial and potential accelerated pathways in fourth-line CRC and Ewing sarcoma
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibrx Biosciences, Inc. 8-K filings
Get the next INBX 8-K as it lands
Follow INBX for push alerts, or ask the research agent what this filing means.